What counts as a Biotech & Gene Editing stock?

Commercial biotechs earning real money alongside clinical-stage names whose value rests entirely on a pipeline. The score gap between the two is wide and deliberate — a pre-revenue company is graded on what it has, not on what it might become. Membership is curated and hand-maintained: a company earns the tag when the theme is a material driver of its business — either a pure-play, or a larger company for which the theme is a named, reported growth engine. Tangential exposure doesn't qualify. The names below are those in our US universe, ranked by score.

How are the best Biotech & Gene Editing stocks ranked?

Each name is scored on the Bull Rankings quality-growth model — one 0–100 score blending business quality, growth, and valuation — the same score used everywhere on the site. The table ranks them highest first.

How often is the ranking updated?

The universe is re-scored every trading day after the US market close, so the ranking reflects the latest fundamentals and prices.

BIOTECH & GENE EDITING · scores as of Aug 7, 2026

Best Biotech & Gene Editing stocks.

The theme: Commercial biotechs earning real money alongside clinical-stage names whose value rests entirely on a pipeline. The score gap between the two is wide and deliberate — a pre-revenue company is graded on what it has, not on what it might become.

How this ranking works

Standard classifications describe what a company files as, not what it's a bet on. This is a curated list of the Biotech & Gene Editing names in our US universe: the pure-plays, plus the larger companies for which Biotech & Gene Editing is a real, reported driver rather than a passing mention. Each carries the same 0–100 quality-growth score used everywhere on the site (how it's built), and re-scores every trading day.

#	Ticker	Company	Score
1	NBIXPharmaceuticals	Neurocrine Biosciences, Inc.	87.5
2	EXELBiotechnology	Exelixis, Inc.	77.8
3	ALNYBiotechnology	Alnylam Pharmaceuticals, Inc.	75.7
4	INCYBiotechnology	Incyte Corporation	74.9
5	VRTXBiotechnology	Vertex Pharmaceuticals Incorporated	69.5
6	REGNBiotechnology	Regeneron Pharmaceuticals, Inc.	66.5
7	BNTXBiotechnology	BioNTech SE	54.9
8	SRPTBiotechnology	Sarepta Therapeutics, Inc.	41.2
9	BEAMBiotechnology	Beam Therapeutics Inc.	21.3
10	MRNABiotechnology	Moderna, Inc.	20.3
11	NTLABiotechnology	Intellia Therapeutics, Inc.	19.7
12	RAREBiotechnology	Ultragenyx Pharmaceutical Inc.	18.7
13	CRSPBiotechnology	CRISPR Therapeutics AG	18.6
14	IONSBiotechnology	Ionis Pharmaceuticals, Inc.	11.4

The Biotech & Gene Editing group at a glance

Where these companies are filed

The 14 members report under 2 different industries, which is exactly why no standard sector view groups them:

Biotechnology13
Drug Manufacturers - Specialty & Generic1

What kind of businesses these are

Average pillar scores across the 14 scored members, against every stock the model scores:

Pillar	Biotech & Gene Editing	Market	Read
Quality	45.3	56.0	10.7 below
Growth	72.8	61.7	11.1 above
Value	39.3	44.1	4.8 below

Pillars run 0–100 against sector peers. A low Value reading means the group is expensive relative to what it earns, not that the businesses are weak — for an early-stage theme that is the normal shape.

Scores across the group run from NBIX at 87.5 down to IONS at 11.4, with a median of 48.1. A theme is a thesis, not a quality filter — membership says a company is exposed to Biotech & Gene Editing, and the score says what the model makes of the business.

Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.